Table 1 Baseline characteristics of the patients
Characteristics | Patients (n = 135), no. (%) |
|---|---|
Age, years, median (range) | 66 (37–93) |
Sex | |
 Female | 30 (22.2) |
 Male | 105 (77.8) |
BMI status, kg/m2, median (range) | 23.0 (15–31) |
Under-weight (< 18.5 kg/m2) | 14 (10.4) |
Normal (18.5 ≤ BMI < 23 kg/m2) | 53 (39.3) |
Over-weight (23 ≤ BM I < 25 kg/m2) | 37 (27.4) |
Obese (≥ 25 kg/m2) | 31 (23.0) |
Smoking status | |
 Never smoker | 37 (27.4) |
 Ever-smoker | 98 (72.6) |
ECOG PS | |
 0–1 | 129 (95.6) |
 ≥ 2 | 6 (4.4) |
Histologic type | |
 Adenocarcinoma | 67 (49.6) |
 Squamous cell carcinoma | 41 (30.4) |
 Othersa | 27 (20.0) |
PD-L1 expression | |
 Negative | 28 (20.7) |
 Positive | 72 (53.3) |
 Unknown | 35 (25.9) |
Type of ICI | |
 Anti-PD-1 or anti-PD-L 1 monotherapy | 105 (77.8) |
 ICI-based combination therapy | 30 (22.2) |
No. of lines of prior chemotherapy | |
 0 | 30 (22.2) |
 1 | 70 (51.9) |
 2 | 35 (25.9) |
Cause of ICI discontinuation | |
 Progression | 98 (72.6) |
 Toxicity | 12 (8.9) |
 Others | 1 (0.7) |
Best response to ICI | |
 Partial response | 50 (37.0) |
 Stable disease | 37 (27.4) |
 Progressive disease | 48 (35.6) |